Obinutuzumab
Top View
- Radiochemistry, Production Processes, Labeling Methods, and Immunopet Imaging Pharmaceuticals of Iodine-124
- (INN) for Biological and Biotechnological Substances
- Brentuximab Vedotin in Combination with Rituximab, Cyclophosphamide
- (CLL/SLL) TREATMENT REGIMENS (Part 1 of 3) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
- Open Full Page
- 2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
- CHMP Assessment Report
- Obinutuzumab
- PDCO Monthly Report of Opinions on Paediatric Investigation Plans and Other Activities 8-11 December 2020
- Gazyva® (Obinutuzumab)
- The Next Generation of Monoclonal Antibody
- Effect of Kinase Inhibitors on the Therapeutic Properties of Monoclonal Antibodies
- Prescribing Information
- Getting the Facts
- Bispecific Antibodies Targeting Tumor-Associated Antigens And
- Analyses of CD20 Monoclonal Antibody-Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies
- Obinutuzumab for the Treatment of Non-Hodgkin Lymphomas